Relationship between the change of the health examination data and the serum adiponectin level
We performed a follow-up study of medical examination data for partcipants without hypertension, diabetes, dyslipidemia, or hyperuricemia and evaluated changes in medical examination data by differences in serum adiponectin levels.
We collected the medical examination data in 2008 and 2014 of workers in a railway company aged below 40 years in 2008. Participants satisfying all of the following four criteria: (1) systolic blood pressure <140 mmHg, diastolic blood pressure <90 mmHg; (2) glycated hemoglobin (HbA1c) <6.0 %; (3) low-density lipoprotein <140 mg/dl and triglycerides (TG) <150 mg/dl; and (4) uric acid ≤7.0 mg/dl.
The participants were classified into two groups on the basis of their serum adiponectin levels: the high adiponectin level group (high level group) and the low adiponectin level group (low level group). We retrospectively followed changes during 2008–2014 in two groups. Statistical analysis was performed using two-way factorial ANOVA with a 5% significance level.
The mean serum adiponectin levels were 12.40 in the high level group (n=286) and 6.42 in the low level group (n=285). The medical examination parameters showing significantly different changes between the two groups were alanine aminotransferase (ALT; p=0.010), gamma-glutamyl transpeptidase (γ-GTP; p=0.004), TG (p<0.001), estimated glomerular filtration rate (eGFR; p=0.022), and HbA1c (p<0.001).
Our follow-up study of medical examination data showed significant relationship between the changes in ALT, γ-GTP, TG, eGFR, and HbA1c levels and the serum adiponectin level.
Occupational health and safety
Analyzed relationship between the change of the health examination data and the serum adiponectin level
Keyword(s): Epidemiology, Occupational Health and Safety
Qualified on the content I am responsible for because: I have been researched using medical examination data for prevention about life-related disease.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.